Biotechnology News

Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a...

Abivax annonce la réalisation de son offre au public de 920 millions de dollars PARIS, France, 6 juillet 2026 – 22h05 (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (« Abivax...

Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of...

PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and...

WEST PALM BEACH, FL, July 06, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXOD/FOXO) (the “Company”) announces the following mid-year update to shareholders by the Company’s Chief...

Midpoint equity value for planned UAE cell sorting entity highlights significant growth runway in high-infertility, medical-tourism hotspot Senior Strategic Advisor Nadeem Malik, former CEO of...

NETANYA, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), announced today following its April 16, 2026 announcement that its wholly-owned...

PharmAla announces the completion of manufacture of ALA-002 drug substance, as well as a full operational update on the LaNeo Gen 2 patented drug family.

NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new...

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...